Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of “Lung Cancer Management in Indian context”

Noronha, 2016, Lung cancer in the Indian subcontinent, South Asian J Cancer, 5, 95, 10.4103/2278-330X.187571 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Yu, 2014, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann Oncol, 25, 423-, 10.1093/annonc/mdt573 Goss, 2016, Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study, Lancet Oncol, 17, 1643, 10.1016/S1470-2045(16)30508-3 Jain, 2016, Evaluation of epidermal growth factor receptor mutations based on mutation specific immunohistochemistry in non-small cell lung cancer: A preliminary study, Indian J Med Res, 143, 308, 10.4103/0971-5916.182621 Graham, 2018, Worldwide frequency of commonly detected EGFR mutations, Arch Pathol Lab Med, 142, 163, 10.5858/arpa.2016-0579-CP Travis, 2015, Adenocarcinoma, 26 Douillard, 2010, Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial, J Clin Oncol, 10, 744, 10.1200/JCO.2009.24.3030 Billah, 2011, EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens, Cancer Cytopathol, 119, 111, 10.1002/cncy.20151 Cardarella, 2012, The introduction of systematic genomic testing for patients with non-small-cell lung cancer, J Thorac Onco, 7, 1767, 10.1097/JTO.0b013e3182745bcb Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162 Cadranel, 2012, Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2), J Thorac Oncol, 7, 1490, 10.1097/JTO.0b013e318265b2b5 Kerner, 2013, CTMM Air Force Consortium. Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome, PLoS One, 29, e70346, 10.1371/journal.pone.0070346 Rosell, 2009, Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 958, 10.1056/NEJMoa0904554 Liu, 2013, Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing, Int J Clin Exp Pathol, 6, 1880 Serizawa, 2014, Assessment of mutational profile of Japanese lung adenocarcinoma patients by multi target assays: a prospective, single-institute study, Cancer, 120, 1471, 10.1002/cncr.28604 Sun, 2012, High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR /TTF-1 expressions, and clinical features, J Thorac Oncol, 7, 323, 10.1097/JTO.0b013e3182381515 Wu, 2008, Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications, Cancer, 113, 3199, 10.1002/cncr.23925 Bal, 2016, ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India, APMIS, 124, 832, 10.1111/apm.12581 Noronha, 2013, EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy, PLoS One, 8, e61561, 10.1371/journal.pone.0061561 Choughule, 2013, Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients, Indian J Cancer, 50, 107, 10.4103/0019-509X.117023 Chougule, 2013, Frequency of EGFR mutations in 907 lung adenocarcinoma patients of Indian ethnicity, PloS one, 8, e76164, 10.1371/journal.pone.0076164 Singh, 2018, Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: a study from India, Curr Probl Cancer Veldore, 2013, Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India, Indian J Cancer, 50, 87, 10.4103/0019-509X.117013 Sahoo, 2011, Screening for EGFR mutations in lung cancer, a report from India, Lung Cancer, 73, 316, 10.1016/j.lungcan.2011.01.004 Shigematsu, 2006, Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, 118, 257, 10.1002/ijc.21496 Yang, 2005, Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer, Clin Cancer Res, 11, 2106, 10.1158/1078-0432.CCR-04-1853 Zhang, 2019, Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment, Transl Lung Cancer Res, 8, 302, 10.21037/tlcr.2019.04.12 Kate, 2019, Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis, Lung Cancer (Auckl), 10, 1 Wei, 2014, Patients harboring epidermal growth factor receptor (EGFR) double mutations had a lower objective response rate than those with a single mutation in non-small cell lung cancer when treated with EGFR -tyrosine kinase inhibitors, Thorac Cancer, 5, 126, 10.1111/1759-7714.12068 Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Inukai, 2006, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer, Cancer Res, 66, 7854, 10.1158/0008-5472.CAN-06-1951 Yu, 2014, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann Oncol, 25, 423, 10.1093/annonc/mdt573 Oxnard, 2017, OA 06.02 Final report of the INHERIT EGFR Study - 33 unrelated kindreds carrying germline EGFR mutations, J Thorac Oncol, 12, S1758, 10.1016/j.jtho.2017.09.355 Lou, 2016, Germline mutation of T790M and dual/multiple EGFR mutations in patients with lung adenocarcinoma, Clin Lung Cancer, 17, e5, 10.1016/j.cllc.2015.11.003 Lindeman, 2018, J Mol Diagn, 20, 129, 10.1016/j.jmoldx.2017.11.004 Goto, 2012, An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting, Ann Oncol, 23, 2914, 10.1093/annonc/mds121 Jain, 2017, Use of exfoliative specimens and fine-needle aspiration smears for mutation testing in lung adenocarcinoma, Acta Cytol, 61, 455, 10.1159/000479217